The impact of short-chain fatty acid–producing bacteria of the gut microbiota in hyperuricemia and gout diagnosis


Por: Martínez-Nava G.A., Méndez-Salazar E.O., Vázquez-Mellado J., Zamudio-Cuevas Y., Francisco-Balderas A., Martínez-Flores K., Fernández-Torres J., Lozada-Pérez C., Guido-Gómora D.L., Martínez-Gómez L.E., Jiménez-Gutiérrez G.E., Pineda C., Silveira L.H., Sánchez-Chapul L., Sánchez-Sánchez R., Camacho-Rea M.C., Martínez-Armenta C., Burguete-García A.I., Orbe-Orihuela C., Lagunas-Martínez A., Palacios-González B., López-Reyes A.

Publicada: 1 ene 2023
Resumen:
Introduction/objectives: Persistent hyperuricemia is a key factor in gout; however, only 13.5% of hyperuricemic individuals manifest the disease. The gut microbiota could be one of the many factors underlying this phenomenon. We aimed to assess the difference in taxonomic and predicted functional profiles of the gut microbiota between asymptomatic hyperuricemia (AH) individuals and gout patients. Methods: The V3–V4 region of the 16S rRNA gene of the gut microbiota of AH individuals, gout patients, and controls was sequenced. Bioinformatic analyses were carried out with QIIME2 and phyloseq to determine the difference in the relative abundance of bacterial genera among the study groups. Tax4fun2 was used to predict the functional profile of the gut microbiota. Results: AH individuals presented a higher abundance of butyrate- and propionate-producing bacteria than gout patients; however, the latter had more bacteria capable of producing acetate. The abundance of Prevotella genus bacteria was not significantly different between the patients but was higher than that in controls. This result was corroborated by the functional profile, in which AH individuals had less pyruvate oxidase abundance than gout patients and less abundance of an enzyme that regulates glutamate synthetase activation than controls. Conclusion: We observed a distinctive taxonomic profile in AH individuals characterized by a higher abundance of short-chain fatty acid-producing bacteria in comparison to those observed in gout patients. Furthermore, we provide scientific evidence that indicates that the gut microbiota of AH individuals could provide anti-inflammatory mediators, which prevent the appearance of gout flares. Key Points• AH and gout patients both have a higher abundance of Prevotella genus bacteria than controls.• AH individuals’ gut microbiota had more butyrate- and propionate-producing bacteria than gout patients.• The gut microbiome of AH individuals provides anti-inflammatory mediators that could prevent gout flares. © 2022, The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Filiaciones:
Martínez-Nava G.A.:
 Laboratorio de Gerociencias, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Calz México-Xochimilco 289, Coapa, Arenal Tepepan, Mexico City, 14389, Mexico

Méndez-Salazar E.O.:
 Unidad de Vinculación Científica de La Facultad de Medicina UNAM-INMEGEN, Instituto Nacional de Medicina Genómica, Mexico City, Mexico

 Postgraduate Program in ICES, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico

Vázquez-Mellado J.:
 Servicio de Reumatología, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico

Zamudio-Cuevas Y.:
 Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

Francisco-Balderas A.:
 Instituto Mexicano del Seguro Social, Mexico City, Mexico

Martínez-Flores K.:
 Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

Fernández-Torres J.:
 Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

Lozada-Pérez C.:
 Servicio de Reumatología, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

Guido-Gómora D.L.:
 Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico

Martínez-Gómez L.E.:
 Laboratorio de Gerociencias, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Calz México-Xochimilco 289, Coapa, Arenal Tepepan, Mexico City, 14389, Mexico

Jiménez-Gutiérrez G.E.:
 Laboratorio de Gerociencias, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Calz México-Xochimilco 289, Coapa, Arenal Tepepan, Mexico City, 14389, Mexico

Pineda C.:
 Dirección General, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

Silveira L.H.:
 Departamento de Reumatología, Instituto Nacional de Cardiología “Ignacio Chávez”, Mexico City, Mexico

Sánchez-Chapul L.:
 Laboratorio de Enfermedades Neuromusculares, División de Neurociencias Clínicas, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

Sánchez-Sánchez R.:
 Laboratorio de Ingeniería de Tejidos Terapia Celular y Medicina Regenerativa, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico

 Escuela de Ingeniería y Ciencias, Departamento de Bioingeniería, Instituto Tecnológico de Monterrey, Mexico City, Mexico

Camacho-Rea M.C.:
 Departamento de Nutrición Animal, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Secretaria de Salud, Mexico City, Mexico

Martínez-Armenta C.:
 Laboratorio de Gerociencias, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Calz México-Xochimilco 289, Coapa, Arenal Tepepan, Mexico City, 14389, Mexico

Burguete-García A.I.:
 Departamento de Epidemiología Genética, Centro de Investigaciones Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico

Orbe-Orihuela C.:
 Departamento de Epidemiología Genética, Centro de Investigaciones Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico

Lagunas-Martínez A.:
 Departamento de Epidemiología Genética, Centro de Investigaciones Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico

Palacios-González B.:
 Unidad de Vinculación Científica de La Facultad de Medicina UNAM-INMEGEN, Instituto Nacional de Medicina Genómica, Mexico City, Mexico

López-Reyes A.:
 Laboratorio de Gerociencias, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Calz México-Xochimilco 289, Coapa, Arenal Tepepan, Mexico City, 14389, Mexico
ISSN: 07703198
Editorial
Springer London, 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 42 Número: 1
Páginas: 203-214
WOS Id: 000864549500001
ID de PubMed: 36201123